Publication Date
1-1-2024
Journal
Pediatric and Developmental Pathology
DOI
10.1177/10935266241230600
PMID
38468555
PMCID
PMC11340240
PubMedCentral® Posted Date
3-11-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Humans, Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-bcl-2, Adolescent, Male, Translocation, Genetic, Child, Female, Diagnosis, Differential, Biomarkers, Tumor, Chromosomes, Human, Pair 14, Neoplasm Recurrence, Local, Chromosomes, Human, Pair 8, BCL2, Burkitt, DLBCL, aggressive b-cell non-Hodgkin lymphoma, B-NHL, ICC, WHO-HAEM5, pediatric
Abstract
We present 2 diagnostically challenging cases of pediatric/adolescent relapsed/refractory aggressive mature B-cell non-Hodgkin lymphoma (B-NHL) within the spectrum of Burkitt lymphoma and diffuse large B-cell lymphoma and illustrate the different therapeutic regimens that are employed for pediatric and adult cancer centers. Both cases displayed varying-sized lymphoma cells with occasional single prominent nucleoli and heterogeneous BCL2 expression. Cytogenetics revealed complex karyotypes with t(8:14)(q24.2;q32) and IGH::MYC rearrangement by FISH. Next generation sequencing revealed deleterious TP53 and MYC mutations. We concluded that both could be diagnosed as “DLBCL-NOS with MYC rearrangement” using the current pathologic classifications, 2022 International Consensus Classification (ICC) and World Health Organization Classifications of Haematolymphoid Tumors (WHO-HAEM5). This report illustrates diagnostic challenges and treatment dilemmas that may be encountered, particularly for adolescent and young adults (AYA).
Included in
Immunology of Infectious Disease Commons, Immunopathology Commons, Medical Immunology Commons, Oncology Commons, Pathology Commons, Pediatrics Commons